Treatment of PTLD has been importantly strengthened by Rituximab, a humanized anti-CD20 antibody, which has been widely approved against CD20 positive malignant lymphoma including DLBCL [23]. This evidence concerns the gene MS4A1 and post-transplant lymphoproliferative disease.